DSM Anti-Infectives today inaugurated in the presence of its Global management
and the civil administration of Punjab its new plant at Toansa for the
production of Ampicillin, one of the most widely used first line of therapy
for combating bacterial infections. In this new facility, DSM Anti-Infectives
implements the newly developed enzymatic process for production of Ampicillin,
which is first ever commercial scale implementation of biotechnology for
producing this Active Pharmaceutical Ingredient (API). The new technology
produces Ampicillin while generating significantly lower amounts of waste as
compared to the conventional processes. The new facility of DSM
Anti-Infectives will cater to Asia Pacific, Middle- East and African
countries, in addition to the Indian market, and the product will be branded
“Puricillin™”.
Speaking before the inaugural ceremony, Stefan Doboczky, President of DSM
Anti-Infectives said, “We have a long-term commitment to the emerging Global
market and India in particular. This new plant is a part of DSM
Anti-Infectives plans to further build a sustainable manufacturing base in
India, and this multimillion dollars investment is a logical consequence of
the other substantial investments we have already made in India Green
production routes to generic API’s. This very well fits into DSM’s vision to
grow in emerging economies. We are proud to build this facility
one-of-its-kind facility in the world. But more important, we are confident
that DSM’s technology will contribute substantially to patient wellness and to
our customers via the enhanced quality of the products and to the environment
by the avoidance of waste. We will continue developing innovative technologies
and implementing them for our customers.
Mr. Bharath Sesha, Vice-President, DSM Anti-Infectives Asia, Middle East and
Africa (AMEA) region said, “We are proud to bring this advanced technology in
the industry for the production of Green Ampicillin to our site in Toansa. We
have a strong base in AMEA region and wish to strengthen it through this new
plant. Our Global R&D team enables us to develop innovative means of
production and to give us this proud moment.”
With the new DSM Anti-Infectives plant at Toansa the Group expands also the
capacity for the production of Purimox®, enzymatic Amoxicillin, one of the
most important API’s for human and animal health. The very high purity of
Purimox™ benefiting both patients and customers and similar to Puricilin™
produced without utilizing solvents has since its introduction in 2006 set the
standard in the market for this API.
About DSM
DSM Anti-Infectives is a subsidiary of.DSM – the Life Sciences and Materials
Sciences Company. Royal DSM N.V. creates innovative products and services in
Life Sciences and Materials Sciences that contribute to the quality of life.
DSM’s products and services are used globally in a wide range of markets and
applications, supporting a healthier, more sustainable and more enjoyable way
of life. End markets include human and animal nutrition and health, personal
care, pharmaceuticals, automotive, coatings and paint, electrical and
electronics, life protection and housing. DSM has annual net sales of EUR 9.3
billion and employs some 23,500 people worldwide. The company is headquartered
in the Netherlands, with locations on five continents. DSM is listed on
Euronext Amsterdam. More information: www.dsm.com
DSM Anti-Infectives is the world’s leading supplier of active pharmaceutical
ingredients such as Amoxicillin, Ampicillin, Cephalexin and Cefadroxil; the
worlds most widely used broad spectrum antibiotics for combating bacterial
infections. With its enzymatic production technology for these API’s the group
has a unique position in serving its customers and via them patients with high
quality products produced via environmentally friendly production routes.
